Optometry Times
Outlet metrics
Global
#620291
United States
#310017
Health/Health
#5531
Articles
-
1 week ago |
optometrytimes.com | Sydney M Crago |Modern Retina |Emily Kaiser Maharjan
The FDA has granted 510(k) clearance to BVI Medical for its glaucoma surgical system, called Leos (Laser Endoscopy Ophthalmic System). Leos is designed to introduce a novel, intuitive Laser ECP procedure that can integrate seamlessly into the surgical workflow. Notably this is the only laser system that lowers intraocular pressure by addressing aqueous humor production in a minimally invasive ab interno procedure.
The OSU College of Optometry awards CooperVision with Neal J. Bailey Optometry Medal for Development
1 week ago |
optometrytimes.com | Jordana Joy
The Ohio State University (OSU) College of Optometry has awarded CooperVision its Neal J. Bailey Optometry Medal for Development.1 The award was presented at OSU’s 2025 Visionary Appreciation Event and recognizes the company for its support of educational opportunities for students, including the funding for a new eye care clinic, according to a news release.
-
1 week ago |
optometrytimes.com | Jordana Joy
April 15, 2025By The first 6 patients in the study had an average improvement of 14.9 letters in early treatment diabetic retinopathy study (ETDRS) standard vision tests within 4 to 6 months post transplantation.
-
1 week ago |
optometrytimes.com | Paul Karpecki |Emily Kaiser Maharjan
The landscape of myopia management is evolving rapidly, with growing global awareness and an increasing arsenal of treatment options. In a recent discussion on the FDA's acceptance of Sydnexis's NDA submission for SYD-101, a non-compounded atropine drop indicated for myopia, Paul Karpecki, OD, FAAO, emphasized how the perception of myopia has shifted—from a benign refractive error to a serious medical condition with long-term ocular health implications.
-
1 week ago |
optometrytimes.com | Sydney M Crago |Modern Retina
Oculis Holdings has completed enrollment in both Phase 3 DIAMOND-1 (NCT05066997) and DIAMOND-2 (NCT06172257) trials. These trials are investigating the company’s OCS-01 eye drops for the treatment of diabetic macular degeneration (DME) and are designed as pivotal registration studies to support global marketing applications including NDA submission and approval by the US Food and Drug Administration (FDA).
Optometry Times journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Website
https://optometrytimes.com/Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →